BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, January 24, 2026
Home » Blogs » BioWorld MedTech Perspectives » Researchers pitch alternative treatment method for migraines

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

BioWorld MedTech

Researchers pitch alternative treatment method for migraines

March 15, 2015
By Omar Ford

SIRcorrect

Earlier this month, I had the distinct pleasure of having a sit-down interview with Kenneth Mandato, the lead researcher for the migraine study and an interventional radiologist at Albany medical center, during the Society of Interventional Radiologists Annual meeting held here in Atlanta. During the interview we discussed the prevalence of migraines and a rather old (but underutilized) technique to treat these conditions. Mandato and a team of researchers from Albany Medical Center and the State University New York Empire State College (Saratoga Springs, New York), used a technique called image-guided intranasal sphenopalatine ganglion (SPG) blocks to give patients enough ongoing relief that they required less medication to relieve migraine pain.

Mandato said that the study shows that before treatment, patients reported a visual analogue scale of 8.25 with scores greater than four at least 15 days per month. The day after the SPG block patients' visual analogue scores were cut in half, to an average of 4.10 Thirty days after the procedure patients reported an average score of 5.25 a 36% decrease from pretreatment. About 88% of patients indicated that they required less or no migraine medication for ongoing relief.

Mandato seemed pretty happy about the results and the potential to do even more trials in the future to bolster the results. What was so impressive was the number of calls and media requests Mandato managed during his time at the conference. Migraines are a hot topic. Here's hoping interest in Mandato's work continues.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 23, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 23, 2026.
  • Illustration of human body surrounded by DNA, cell and drug icons

    Cell/gene therapy sector now sustainable; China competition mounting

    BioWorld
    There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
  • Illustration of magnifying glass inspecting brain

    Neurotrimin unveiled as marker in intellectual disability

    BioWorld Science
    Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
  • DNA mutations or genetic disorder concept art

    Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

    BioWorld Science

    Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing